Which has preferable valuation & earnings, ALC or COO?

Alcon has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alcon $10.40B 3.10 $980M $1.31 49.72 Cooper Companies $4.24B 2.41 $374.90M $2.93 18.35

Is ALC or COO more profitable?

Cooper Companies has a net margin of 13.46% compared to Alcon's net margin of 5.92%. Cooper Companies' return on equity of 10.90% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets Alcon 5.92% 7.29% 5.09% Cooper Companies 13.46% 10.90% 7.24%

Does the media prefer ALC or COO?

In the previous week, Cooper Companies had 62 more articles in the media than Alcon. MarketBeat recorded 65 mentions for Cooper Companies and 3 mentions for Alcon. Alcon's average media sentiment score of 0.28 beat Cooper Companies' score of 0.27 indicating that Alcon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alcon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cooper Companies 19 Very Positive mention(s) 9 Positive mention(s) 13 Neutral mention(s) 16 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts recommend DXCM or ALC?

DexCom presently has a consensus target price of $88.71, suggesting a potential upside of 0.89%. Alcon has a consensus target price of $84.96, suggesting a potential upside of 30.44%. Given Alcon's higher possible upside, analysts clearly believe Alcon is more favorable than DexCom. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 1 Sell rating(s) 2 Hold rating(s) 21 Buy rating(s) 2 Strong Buy rating(s) 2.92 Alcon 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61

Which has preferable earnings & valuation, DXCM or ALC?

Alcon has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 7.12 $836.30M $2.53 34.75 Alcon $10.40B 3.10 $980M $1.31 49.72

Is DXCM or ALC more profitable?

DexCom has a net margin of 20.12% compared to Alcon's net margin of 5.92%. DexCom's return on equity of 35.94% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Alcon 5.92% 7.29% 5.09%

Does the media favor DXCM or ALC?

In the previous week, DexCom had 14 more articles in the media than Alcon. MarketBeat recorded 17 mentions for DexCom and 3 mentions for Alcon. DexCom's average media sentiment score of 0.50 beat Alcon's score of 0.28 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alcon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MDLN or ALC?

Medline has higher revenue and earnings than Alcon. Medline is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.49 $1.16B $0.79 40.66 Alcon $10.40B 3.10 $980M $1.31 49.72

Is MDLN or ALC more profitable?

Alcon has a net margin of 5.92% compared to Medline's net margin of 0.00%. Alcon's return on equity of 7.29% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Alcon 5.92% 7.29% 5.09%

Does the media prefer MDLN or ALC?

In the previous week, Medline had 9 more articles in the media than Alcon. MarketBeat recorded 12 mentions for Medline and 3 mentions for Alcon. Medline's average media sentiment score of 0.75 beat Alcon's score of 0.28 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Alcon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WST or ALC?

In the previous week, West Pharmaceutical Services had 17 more articles in the media than Alcon. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 3 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.81 beat Alcon's score of 0.28 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 15 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alcon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ALC or SOLV?

Solventum has lower revenue, but higher earnings than Alcon. Solventum is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alcon $10.40B 3.10 $980M $1.31 49.72 Solventum $8.33B 1.79 $1.56B $8.18 10.69

Is ALC or SOLV more profitable?

Solventum has a net margin of 17.26% compared to Alcon's net margin of 5.92%. Solventum's return on equity of 25.09% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets Alcon 5.92% 7.29% 5.09% Solventum 17.26% 25.09% 8.78%

Does the media refer more to ALC or SOLV?

In the previous week, Solventum had 10 more articles in the media than Alcon. MarketBeat recorded 13 mentions for Solventum and 3 mentions for Alcon. Solventum's average media sentiment score of 0.78 beat Alcon's score of 0.28 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alcon 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alcon (ALC) Competitors

$65.14 -1.16 (-1.75%)

Closing price 09/17/2026 03:59 PM Eastern

Extended Trading

$64.88 -0.26 (-0.40%)

As of 04:36 AM Eastern

Compare

ALC vs. COO, DXCM, MDLN, WST, and SOLV

Should you buy Alcon stock or one of its competitors? Alcon's main competitors and comparable companies include Cooper Companies (COO), DexCom (DXCM), Medline (MDLN), West Pharmaceutical Services (WST), and Solventum (SOLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Alcon compare to Cooper Companies?

Alcon (NYSE:ALC) and Cooper Companies (NASDAQ:COO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Cooper Companies has a net margin of 13.46% compared to Alcon's net margin of 5.92%. Cooper Companies' return on equity of 10.90% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alcon	5.92%	7.29%	5.09%
Cooper Companies	13.46%	10.90%	7.24%

In the previous week, Cooper Companies had 62 more articles in the media than Alcon. MarketBeat recorded 65 mentions for Cooper Companies and 3 mentions for Alcon. Alcon's average media sentiment score of 0.28 beat Cooper Companies' score of 0.27 indicating that Alcon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cooper Companies	19 Very Positive mention(s)	9 Positive mention(s)	13 Neutral mention(s)	16 Negative mention(s)	2 Very Negative mention(s)	Neutral

Alcon currently has a consensus target price of $84.96, indicating a potential upside of 30.44%. Cooper Companies has a consensus target price of $71.47, indicating a potential upside of 32.89%. Given Cooper Companies' higher probable upside, analysts plainly believe Cooper Companies is more favorable than Alcon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Cooper Companies	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.11

Alcon has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Alcon has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alcon	$10.40B	3.10	$980M	$1.31	49.72
Cooper Companies	$4.24B	2.41	$374.90M	$2.93	18.35

53.9% of Alcon shares are held by institutional investors. Comparatively, 24.4% of Cooper Companies shares are held by institutional investors. 1.5% of Alcon shares are held by company insiders. Comparatively, 2.1% of Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Alcon beats Cooper Companies on 10 of the 17 factors compared between the two stocks.

How does Alcon compare to DexCom?

DexCom (NASDAQ:DXCM) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

DexCom presently has a consensus target price of $88.71, suggesting a potential upside of 0.89%. Alcon has a consensus target price of $84.96, suggesting a potential upside of 30.44%. Given Alcon's higher possible upside, analysts clearly believe Alcon is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

DexCom has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Alcon has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

97.8% of DexCom shares are held by institutional investors. Comparatively, 53.9% of Alcon shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.5% of Alcon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alcon has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.12	$836.30M	$2.53	34.75
Alcon	$10.40B	3.10	$980M	$1.31	49.72

DexCom has a net margin of 20.12% compared to Alcon's net margin of 5.92%. DexCom's return on equity of 35.94% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Alcon	5.92%	7.29%	5.09%

In the previous week, DexCom had 14 more articles in the media than Alcon. MarketBeat recorded 17 mentions for DexCom and 3 mentions for Alcon. DexCom's average media sentiment score of 0.50 beat Alcon's score of 0.28 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DexCom beats Alcon on 12 of the 17 factors compared between the two stocks.

How does Alcon compare to Medline?

Medline (NASDAQ:MDLN) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Medline presently has a consensus price target of $47.42, suggesting a potential upside of 47.64%. Alcon has a consensus price target of $84.96, suggesting a potential upside of 30.44%. Given Medline's stronger consensus rating and higher probable upside, research analysts plainly believe Medline is more favorable than Alcon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.83
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Alcon has a net margin of 5.92% compared to Medline's net margin of 0.00%. Alcon's return on equity of 7.29% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Alcon	5.92%	7.29%	5.09%

In the previous week, Medline had 9 more articles in the media than Alcon. MarketBeat recorded 12 mentions for Medline and 3 mentions for Alcon. Medline's average media sentiment score of 0.75 beat Alcon's score of 0.28 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.9% of Alcon shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Comparatively, 1.5% of Alcon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medline has higher revenue and earnings than Alcon. Medline is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.49	$1.16B	$0.79	40.66
Alcon	$10.40B	3.10	$980M	$1.31	49.72

Summary

Medline and Alcon tied by winning 8 of the 16 factors compared between the two stocks.

How does Alcon compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

West Pharmaceutical Services has a net margin of 16.98% compared to Alcon's net margin of 5.92%. West Pharmaceutical Services' return on equity of 20.11% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
Alcon	5.92%	7.29%	5.09%

West Pharmaceutical Services has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Alcon has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 53.9% of Alcon shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 1.5% of Alcon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

West Pharmaceutical Services presently has a consensus target price of $379.08, suggesting a potential upside of 3.38%. Alcon has a consensus target price of $84.96, suggesting a potential upside of 30.44%. Given Alcon's higher possible upside, analysts plainly believe Alcon is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Alcon has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.33B	7.76	$493.70M	$7.81	46.95
Alcon	$10.40B	3.10	$980M	$1.31	49.72

In the previous week, West Pharmaceutical Services had 17 more articles in the media than Alcon. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 3 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.81 beat Alcon's score of 0.28 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	15 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

West Pharmaceutical Services beats Alcon on 11 of the 17 factors compared between the two stocks.

How does Alcon compare to Solventum?

Alcon (NYSE:ALC) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

53.9% of Alcon shares are held by institutional investors. 1.5% of Alcon shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alcon currently has a consensus target price of $84.96, suggesting a potential upside of 30.44%. Solventum has a consensus target price of $92.80, suggesting a potential upside of 6.08%. Given Alcon's stronger consensus rating and higher probable upside, research analysts clearly believe Alcon is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Solventum	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Solventum has lower revenue, but higher earnings than Alcon. Solventum is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alcon	$10.40B	3.10	$980M	$1.31	49.72
Solventum	$8.33B	1.79	$1.56B	$8.18	10.69

In the previous week, Solventum had 10 more articles in the media than Alcon. MarketBeat recorded 13 mentions for Solventum and 3 mentions for Alcon. Solventum's average media sentiment score of 0.78 beat Alcon's score of 0.28 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.26% compared to Alcon's net margin of 5.92%. Solventum's return on equity of 25.09% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alcon	5.92%	7.29%	5.09%
Solventum	17.26%	25.09%	8.78%

Alcon has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Solventum has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Alcon beats Solventum on 10 of the 17 factors compared between the two stocks.

Get Alcon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALC vs. The Competition

Export

Metric	Alcon	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$32.79B	$5.54B	$7.20B	$23.00B
Dividend Yield	N/A	1.79%	2.57%	3.60%
P/E Ratio	49.72	25.20	273.24	28.31
Price / Sales	3.10	70.43	629.82	20.35
Price / Cash	12.09	32.74	77.01	33.29
Price / Book	1.46	5.76	10.49	4.69
Net Income	$980M	$151.55M	$3.48B	$1.07B
7 Day Performance	-1.41%	0.93%	0.77%	-1.11%
1 Month Performance	-11.59%	-3.07%	-0.32%	-3.07%
1 Year Performance	-16.27%	13.32%	18.69%	8.10%

Alcon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALC Alcon	3.5104 of 5 stars	$65.14 -1.8%	$84.96 +30.4%	-15.6%	$32.79B	$10.40B	49.72	25,942	Analyst Forecast
COO Cooper Companies	4.4271 of 5 stars	$69.59 flat	$81.64 +17.3%	-16.4%	$13.57B	$4.09B	58.97	15,000	Trending News Insider Trade Buyback Announcement
DXCM DexCom	3.0118 of 5 stars	$87.90 flat	$88.71 +0.9%	+15.0%	$33.17B	$4.66B	34.74	11,000	Positive News Insider Trade
MDLN Medline	3.3995 of 5 stars	$36.59 flat	$47.42 +29.6%	N/A	$48.11B	$28.43B	46.32	45,000	Positive News
WST West Pharmaceutical Services	2.936 of 5 stars	$339.90 0.0%	$368.08 +8.3%	+43.0%	$23.93B	$3.07B	43.52	10,800	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ALC) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alcon (ALC) Competitors

ALC vs. COO, DXCM, MDLN, WST, and SOLV

How does Alcon compare to Cooper Companies?

Summary

How does Alcon compare to DexCom?

Summary

How does Alcon compare to Medline?

Summary

How does Alcon compare to West Pharmaceutical Services?

Summary

How does Alcon compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALC vs. The Competition

Alcon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alcon (ALC) Competitors

ALC vs. COO, DXCM, MDLN, WST, and SOLV

How does Alcon compare to Cooper Companies?

Is ALC or COO more profitable?

Does the media prefer ALC or COO?

Do analysts prefer ALC or COO?

Which has more volatility and risk, ALC or COO?

Which has preferable valuation & earnings, ALC or COO?

Do institutionals & insiders have more ownership in ALC or COO?

Summary

How does Alcon compare to DexCom?

Do analysts recommend DXCM or ALC?

Which has more volatility & risk, DXCM or ALC?

Do insiders and institutionals believe in DXCM or ALC?

Which has preferable earnings & valuation, DXCM or ALC?

Is DXCM or ALC more profitable?

Does the media favor DXCM or ALC?

Summary

How does Alcon compare to Medline?

Do analysts recommend MDLN or ALC?

Is MDLN or ALC more profitable?

Does the media prefer MDLN or ALC?

Do insiders and institutionals hold more shares of MDLN or ALC?

Which has preferable valuation & earnings, MDLN or ALC?

Summary

How does Alcon compare to West Pharmaceutical Services?

Is WST or ALC more profitable?

Which has more volatility & risk, WST or ALC?

Do insiders & institutionals hold more shares of WST or ALC?

Do analysts recommend WST or ALC?

Which has stronger valuation and earnings, WST or ALC?

Does the media prefer WST or ALC?

Summary

How does Alcon compare to Solventum?

Do institutionals & insiders hold more shares of ALC or SOLV?

Do analysts prefer ALC or SOLV?

Which has better earnings & valuation, ALC or SOLV?

Does the media refer more to ALC or SOLV?

Is ALC or SOLV more profitable?

Which has more risk & volatility, ALC or SOLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALC vs. The Competition

Alcon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools